NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer by unknown
MEETING ABSTRACT Open Access
NKP-1339, a first-in-class anticancer drug showing
mild side effects and activity in patients suffering
from advanced refractory cancer
Robert Trondl1,3, Petra Heffeter2,3, Michael A Jakupec1,3, Walter Berger2,3, Bernhard K Keppler1,3*
From 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the
Croatian, Serbian and Slovenian Pharmacological Societies.
Graz, Austria. 20-21 September 2012
Background
NKP-1339 is one of the most promising investigational
non-platinum metal drugs in clinical development against
solid malignancies. Recently, NKP-1339 was evaluated in a
clinical phase I trial regarding its safety, tolerability, maxi-
mum tolerated dose, pharmacokinetics, and pharmacody-
namics. The high tumor targeting potential of NKP-1339
is probably based on delivery to tumor sites by serum pro-
teins such as albumin and transferrin as well as on the
activation of the compound in the reductive tumor milieu.
The reduction of ruthenium(III) to ruthenium(II) is
favoured under hypoxic condition (frequently occurring in
solid tumors) and is followed by severe disruption of the
cellular redox balance and induction of apoptosis via the
mitochondrial pathway.
Methods
In the recently completed clinical phase I trial 34 patients
with advanced solid tumors were enrolled for dose escala-
tion [1]. NKP-1339 was infused on day 1, 8, and 15 of
28-day cycles. To gain further insight in the mechanism of
action, protein expression studies in cancer cells exposed
in vitro were performed.
Results
The maximum tolerated dose of NKP-1339 was deter-
mined at 625 mg/m2, and the most common drug-related
side effects were nausea, vomiting, and fatigue. A long-
lasting partial response was observed in 1 patient with a
gastro-intestinal neuroendocrine tumor (NET), and 7
patients having experienced stable disease, including
NET (2), non-small-cell lung cancer (2), colorectal cancer
(1), sarcoma (1), and cancer of unknown primary (1).
Moreover, NKP-1339 was found to down-regulate in
cancer cell lines the ER chaperon GRP78, a key regulator
of the unfolded protein response, which is associated
with intrinsic and chemotherapy-induced resistance.
Conclusions
The very limited side effects of NKP-1339 and the activity
observed in a variety of tumors so far are very promising.
Further clinical phase I drug combination studies and
single agent phase II studies are planned.
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